On May 15, 2020 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, reported it will release its unaudited financial results for the quarter ended March 31, 2020 on Wednesday, May 20, 2020, before the US markets open (Press release, BioLineRx, MAY 15, 2020, View Source [SID1234558176]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call on Wednesday, May 20, 2020 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-888-668-9141 from the U.S. or +972-3-918-0609 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until May 22, 2020; please dial +1-888-782-4291 from the U.S. or +972-3-925-5928 internationally.

On May 15, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, taking place on June 22-24, 2020 (Press release, BeiGene, MAY 15, 2020, View Source [SID1234558175]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations:

Title: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
Abstract #: 9496
Poster Board #: CT253
Session Category: CT01 Phase 1 Adult Clinical Trial
Session Title: Phase 1 Trials in Progress
Lead Author: Jayesh Desai, MBBS, FRACP, Peter MacCallum Center Centre, Australia

Title: BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo
Abstract #: 664
Poster Board #: 11
Session Category: Experimental and Molecular Therapeutics
Session Title: PI3K/AKT/mTOR Inhibitors
Lead Author: Xiao Yang, BeiGene

Title: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models
Abstract #: 3077
Poster Board #: 11
Session Category: Experimental and Molecular Therapeutics
Session Title: Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents
Lead Author: Nan Hu, BeiGene

Title: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Abstract #: 6415
Poster Board #: 9
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Therapeutic Approaches
Lead Author: Xi Yuan, BeiGene

On May 15, 2020 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, reported that it will showcase key programs focused on novel targets in neurodegenerative diseases at next week’s UBS Virtual Global Healthcare Conference (May 18–20, 2020) (Press release, AC Immune, MAY 15, 2020, View Source [SID1234558174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speaking on May 20th, Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, will outline the cutting-edge science behind AC Immune’s therapeutic and diagnostic programs in TDP-43 and alpha-synuclein – which are amongst the most comprehensive in the field. Both targets are considered to be major pathologies in neurodegenerative diseases, and increasingly thought to be important co-pathologies in Alzheimer’s disease and Parkinson’s disease. This highlights the need for the precision medicine approach pioneered by AC Immune to achieve earlier and more accurate diagnosis.

In addition to the Company’s TDP-43 and alpha-synuclein targeting programs, the presentation will also detail advances for the clinical stage assets addressing the well-established pathophysiology mediated by Tau and Abeta. The critical role of the Company’s two proprietary platforms, SupraAntigen and Morphomer, in fueling advances for antibodies and small molecules, respectively, will also be highlighted.

UBS Virtual Global Healthcare Conference
Date: May 20, 2020 | 9:10–10:00 am ET/ 3:10–4:00 pm CET
Format: Virtual presentation
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

A webcast of the presentation will be available on the Events Page of AC Immune’s website.

On May 15, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held on June 22-24, 2020 (Press release, Affimed, MAY 15, 2020, View Source [SID1234558173]). Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Abstract: 5659

Authors: Uwe Reusch, Michael Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller, Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael Tesar. Affimed GmbH, Heidelberg, Germany

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

Title: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma

Abstract: 6987

Authors: Satoko Kakiuchi-Kiyota, Melissa Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Luna Liu, Sivan Cohen, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida-Nagata, Shelly Zhong, Michael Dillon, Christoph Spiess, Steve Leong, Bing Zheng. Genentech Inc.; Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Thorsten Ross. Affimed; Andy Polson, Ayse Meric Ovacik. Genentech Inc.

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

More details about the programs for the AACR (Free AACR Whitepaper) Virtual Annual Meeting II are available online at www.aacr.org.

Conference Call Information

Affimed will host a live teleconference today, Friday May 15th at 8am Eastern to discuss the abstracts and recent corporate developments. The teleconference details will be available in the "Webcasts" section on the "Investors" page of the Affimed website at View Source, and a replay of the teleconference will be accessible at the same link for 30 days following the call.

On May 15, 2020 BioInvent International AB ("BioInvent") (OMXS: BINV) reported the presentation of promising new data on its anti-tumor necrosis factor receptor 2 (TNFR2) program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, BioInvent, MAY 15, 2020, View Source [SID1234558172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key results:

Targeting TNFR2 demonstrates compelling therapeutic effects in syngeneic solid cancer models spanning "hot" and "cold" tumors.
Targeting TNFR2 synergizes with anti-PD-1 to achieve cure.
Careful mechanistic dissection and matching of the human lead clinical candidates and mouse surrogate antibodies enables thorough understanding of TNFR2-targeting and critical guidance of clinical development.
The exciting translational data package will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, taking place June 22-24. The abstract is posted online today.

TNFR2 is particularly upregulated on tumor-associated regulatory T cells (Tregs) and has been shown to be important for their expansion and survival. As a part of its Treg program, BioInvent identified and characterized a wide panel of TNFR2-specific antibodies, generated from its proprietary n-CoDeR library and unique F.I.R.S.TTM discovery tool.

Two antibody variants with distinct molecular and functional properties have been selected for development for treatment of solid cancer based on careful characterization of their mechanisms of action: BI-1808, a ligand-blocking Treg depleting antibody, and BI-1910, a TNFR2 agonist. The two antibody candidates showed strikingly different FcgR-dependence for optimal antitumor activity and – while evoking different initial immune cell mediated events – both elicited transformation of the tumor immune landscape associated with powerful anti-tumor efficacy.

Martin Welschof, CEO of BioInvent, says: "The selection of these promising antibodies is a further demonstration of the efficacy of BioInvent’s proprietary F.I.R.S.T technology platform, a patient-centric approach allowing for the discovery of human antibodies, targets and pathways, using our state-of-the-art n-CoDeR antibody library. These two anti-TNFR2 antibodies displayed potent anti-tumor efficacy across several in vivo cancer models, both as single agents and when combined with anti-PD-1, which make them very exciting compounds for further development."

Title of the poster: "Targeting TNFR2 for Cancer Immunotherapy – Ligand blocking depletors versus receptor agonists"
Authors: Linda Mårtensson, Kirstie Cleary, Monika Semmrich, Mathilda Kovacek, Petra Holmkvist, Caroline Svensson, Mimoza Demiri, Therese Blidberg, Ulla-Carin Thornberg, Vincentiu Pitic, Osman Dadas, Sean H Lim, Stephen A Beers, Mark S Cragg, Björn Frendéus, Ingrid Teige
Abstract Number: 5892
Session Date and Time: June 22-24, 2020
Poster Session Title: Immune Checkpoints 1
Poster Number: 936